Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread

Journal of General Virology

Volumn 93, Issue PART 12, 2012, Pages 2601-2605

  Mahlakõiv, Tanel ^a   Ritz, Daniel ^b   Mordstein, Markus ^a   DeDiego, Marta L ^c   Enjuanes, Luis ^c   Müller, Marcel A ^b   Drosten, Christian ^b   Staeheli, Peter ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERFERON 3; INTERLEUKIN 28R1 ANTIBODY; MONOCLONAL ANTIBODY; RECEPTOR; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MEGADOSE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LIVER DISEASE; LUNG; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; INTERFERON TYPE I; INTERFERONS; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; SARS VIRUS; STAT1 TRANSCRIPTION FACTOR; VIRUS REPLICATION;

MUS; SARS CORONAVIRUS;

EID: 84869450003     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.046284-0     Document Type: Article

References (32)

1. Aaronson, D. S. & Horvath, C. M. (2002). A road map for those who don't know JAK-STAT. Science 296, 1653-1655.
2. Ank, N., West, H. & Paludan, S. R. (2006). IFN-l: novel antiviral cytokines. J Interferon Cytokine Res 26, 373-379.
3. Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H. & Doerr, H. W. (2003). Treatment of SARS with human interferons. Lancet 362, 293-294.
4. Ding, Y., Wang, H., Shen, H., Li, Z., Geng, J., Han, H., Cai, J., Li, X., Kang, W. & other authors (2003). The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 200, 282-289.
5. Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H. R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L. & other authors (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348, 1967-1976.
6. Farcas, G. A., Poutanen, S. M., Mazzulli, T., Willey, B. M., Butany, J., Asa, S. L., Faure, P., Akhavan, P., Low, D. E. & Kain, K. C. (2005). Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis 191, 193-197.
7. Frieman, M. B., Chen, J., Morrison, T. E., Whitmore, A., Funkhouser, W., Ward, J. M., Lamirande, E. W., Roberts, A., Heise, M. & other authors (2010). SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog 6, e1000849.
8. Glass, W. G., Subbarao, K., Murphy, B. & Murphy, P. M. (2004). Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 173, 4030-4039.
9. Glass, W. G., Lim, J. K., Cholera, R., Pletnev, A. G., Gao, J. L. & Murphy, P. M. (2005). Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 202, 1087-1098.
10. Haagmans, B. L., Kuiken, T., Martina, B. E., Fouchier, R. A., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., de Jong, T., Itamura, S. & other authors (2004). Pegylated interferon-a protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10, 290-293.
11. Haller, O., Kochs, G. & Weber, F. (2006). The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344, 119-130.
12. Hensley, L. E., Fritz, L. E., Jahrling, P. B., Karp, C. L., Huggins, J. W. & Geisbert, T. W. (2004). Interferon-b 1a and SARS coronavirus replication. Emerg Infect Dis 10, 317-319.
13. Hickey, M. J., Held, K. S., Baum, E., Gao, J. L., Murphy, P.M. & Lane, T. E. (2007). CCR1 deficiency increases susceptibility to fatal coronavirus infection of the central nervous system. Viral Immunol 20, 599-608.
14. Hogan, R. J., Gao, G., Rowe, T., Bell, P., Flieder, D., Paragas, J., Kobinger, G. P., Wivel, N. A., Crystal, R. G. & other authors (2004). Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol 78, 11416-11421.
15. Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H. & Donnelly, R. P. (2003). IFN-ls mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4, 69-77.
16. Le Bon, A. & Tough, D. F. (2002). Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14, 432-436.
17. Leung, W. K., To, K. F., Chan, P. K., Chan, H. L., Wu, A. K., Lee, N., Yuen, K. Y. & Sung, J. J. (2003). Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 125, 1011-1017.
18. Mellado, M., Rodríguez-Frade, J. M., Mañes, S. & Martínez-A, C. (2001). Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol 19, 397-421.
19. Mordstein, M., Kochs, G., Dumoutier, L., Renauld, J. C., Paludan, S. R., Klucher, K. & Staeheli, P. (2008). Interferon-l contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4, e1000151.
20. Mordstein, M., Neugebauer, E., Ditt, V., Jessen, B., Rieger, T., Falcone, V., Sorgeloos, F., Ehl, S., Mayer, D. & other authors (2010). Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84, 5670-5677.
21. Morrow, M. P., Pankhong, P., Laddy, D. J., Schoenly, K. A., Yan, J., Cisper, N. & Weiner, D. B. (2009). Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113, 5868-5877.
22. Peiris, J. S., Chu, C. M., Cheng, V. C., Chan, K. S., Hung, I. F., Poon, L. L., Law, K. I., Tang, B. S., Hon, T. Y. & other authors (2003a). Clinical progression and viral load in a community outbreak of coronavirusassociated SARS pneumonia: a prospective study. Lancet 361, 1767-1772.
23. Peiris, J. S., Lai, S. T., Poon, L. L., Guan, Y., Yam, L. Y., Lim, W., Nicholls, J., Yee, W. K., Yan, W. W. & other authors (2003b). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325.
24. Pott, J., Mahlakõ IV, T., Mordstein, M., Duerr, C. U., Michiels, T., Stockinger, S., Staeheli, P. & Hornef, M. W. (2011). IFN-l determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108, 7944-7949.
25. Radonić, A., Thulke, S., Mackay, I. M., Landt, O., Siegert, W. & Nitsche, A. (2004). Guideline to reference gene selection for quantitative realtime PCR. Biochem Biophys Res Commun 313, 856-862.
26. Roberts, A., Deming, D., Paddock, C. D., Cheng, A., Yount, B., Vogel, L., Herman, B. D., Sheahan, T., Heise, M. & other authors (2007). A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3, e5.
27. Sadler, A. J. & Williams, B. R. (2008). Interferon-inducible antiviral effectors. Nat Rev Immunol 8, 559-568.
28. Sheahan, T., Morrison, T. E., Funkhouser, W., Uematsu, S., Akira, S., Baric, R. S. & Heise, M. T. (2008). MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 4, e1000240.
29. Skowronski, D. M., Astell, C., Brunham, R. C., Low, D. E., Petric, M., Roper, R. L., Talbot, P. J., Tam, T. & Babiuk, L. (2005). Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 56, 357-381.
30. Uzé, G., Schreiber, G., Piehler, J. & Pellegrini, S. (2007). The receptor of the type I interferon family. Curr Top Microbiol Immunol 316, 71-95.
31. Zheng, B., He, M. L., Wong, K. L., Lum, C. T., Poon, L. L., Peng, Y., Guan, Y., Lin, M. C. & Kung, H. F. (2004). Potent inhibition of SARSassociated coronavirus (SCOV) infection and replication by type I interferons (IFN-a/b) but not by type II interferon (IFN-c). J Interferon Cytokine Res 24, 388-390.
32. Zhou, Z., Hamming, O. J., Ank, N., Paludan, S. R., Nielsen, A. L. & Hartmann, R. (2007). Type III interferon (IFN) induces a type I IFNlike response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81, 7749-7758.